Core Insights - Pasithea Therapeutics Corp. is set to present its next-generation macrocyclic MEK inhibitor, PAS-004, at the 2025 CAGLA NeauxCancer Conference, highlighting its potential in treating neurofibromatosis type 1 (NF1) and other cancer indications [1][2] - The presentation will include interim safety, tolerability, and pharmacokinetic data from an ongoing Phase 1 study involving advanced cancer patients with MAPK pathway-driven tumors [2] - The CAGLA NeauxCancer Conference is a significant event for oncology researchers and industry professionals, focusing on advancements in cancer treatment [3] Company Overview - Pasithea Therapeutics is a biotechnology firm dedicated to developing innovative treatments for central nervous system disorders and RASopathies, with a focus on conditions like NF1, solid tumors, and ALS [4] - The company boasts a team of experts in neuroscience, translational medicine, and drug development, aiming to create new molecular entities for various neurological disorders [4]
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference